Need for improved global measurement of early childhood respiratory syncytial virus disease
- PMID: 35598609
- DOI: 10.1016/S0140-6736(22)00623-7
Need for improved global measurement of early childhood respiratory syncytial virus disease
Conflict of interest statement
TVH reports grants from the US National Institutes of Health (NIH) and WHO, serves as a Co-chair of the American Thoracic Society (ATS) Vaccines and Immunization Working Group, serves as a member of the US National Asthma Education Prevention Program expert panel, serves as a member of the ATS publications committee, serves as a Data and Safety Monitoring Board (DSMB) member for a Pfizer RSV vaccine trial, and has served on Pfizer and Sanofi-Pasteur RSV advisory boards, all unrelated to the topic of this Comment. JRO reports grants from the NIH and Pfizer, participation on the Moderna Product Pipeline Advisory Board, participation on the Pfizer Immunization for All Ages Advisory Board, participation on the Seqirus Real World Evidence Advisory Board, participation on the Lumen Bioscience DSMB for LMN-101 followed by Campylobacter jejuni challenge, and serves as a Co-chair of the ATS Vaccines and Immunization Working Group, all unrelated to the topic of this Comment.
Comment on
-
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19. Lancet. 2022. PMID: 35598608 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical